阿尔茨海默病无症状期、轻度认知障碍期和痴呆期生物标志物及认知标志物的时间演变。
Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.
作者信息
Bertens Daniela, Knol Dirk L, Scheltens Philip, Visser Pieter Jelle
机构信息
Department of Neurology/Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands.
Department of Epidemiology and Biostatistics, VU Medical Centre, Amsterdam, The Netherlands.
出版信息
Alzheimers Dement. 2015 May;11(5):511-22. doi: 10.1016/j.jalz.2014.05.1754. Epub 2014 Aug 20.
Abstract
BACKGROUND
We investigated the pattern of disease progression in the asymptomatic, mild cognitive impairment (MCI), and dementia stage of Alzheimer's disease (AD).
METHODS
We selected 284 subjects with AD pathology, defined as abnormal levels of amyloid beta 1-42 (Aβ1-42) in cerebrospinal fluid (CSF). Disease outcome measures included six biomarkers and five cognitive markers. We compared differences in baseline measures and decline over 4 years between the AD stages and tested whether these changes differed from subjects, without AD pathology (N = 132).
RESULTS
CSF Aβ1-42 reached the maximum abnormality level in the asymptomatic stage and tau in the MCI stage. The imaging and cognitive markers started to decline in the asymptomatic stage, and decline accelerated with advancing clinical stage.
CONCLUSION
This study provides further evidence for a temporal evolution of AD biomarkers. Our findings may be helpful to determine stage specific outcome measures for clinical trials.
摘要
背景
我们研究了阿尔茨海默病（AD）无症状期、轻度认知障碍（MCI）期和痴呆期的疾病进展模式。
方法
我们选取了284名患有AD病理特征的受试者，其定义为脑脊液（CSF）中β淀粉样蛋白1-42（Aβ1-42）水平异常。疾病结局指标包括六种生物标志物和五种认知标志物。我们比较了AD各阶段之间的基线测量差异以及4年期间的下降情况，并测试了这些变化是否与无AD病理特征的受试者（N = 132）不同。
结果
CSF Aβ1-42在无症状期达到最大异常水平，tau在MCI期达到最大异常水平。影像学和认知标志物在无症状期开始下降，并随着临床阶段的推进而加速下降。
结论
本研究为AD生物标志物的时间演变提供了进一步证据。我们的研究结果可能有助于确定临床试验中特定阶段的结局指标。
相似文献
1
Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.阿尔茨海默病无症状期、轻度认知障碍期和痴呆期生物标志物及认知标志物的时间演变。
Alzheimers Dement. 2015 May;11(5):511-22. doi: 10.1016/j.jalz.2014.05.1754. Epub 2014 Aug 20.
2
Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.[11C]PIB正电子发射断层扫描（PET）与脑脊液生物标志物在轻度认知障碍和阿尔茨海默病患者样本中的一致性及诊断准确性
J Alzheimers Dis. 2015;45(4):1077-88. doi: 10.3233/JAD-142952.
3
Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.在一个早期富集的轻度认知障碍样本中，用于预测转化和认知衰退的认知标志物和生物标志物的不同强度。
J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.
4
Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.在临床环境中比较脑脊液生物标志物和淀粉样 PET 的诊断性能。
J Alzheimers Dis. 2020;74(2):473-490. doi: 10.3233/JAD-191109.
5
Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.氟代硼替吡咯正电子发射断层扫描与脑脊液生物标志物
Alzheimers Dement. 2015 Aug;11(8):986-93. doi: 10.1016/j.jalz.2015.03.002. Epub 2015 Apr 24.
6
Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.淀粉样蛋白级联和 tau 病理学脑脊液标志物在轻度认知障碍阿尔茨海默病大脑代谢特征方面。
J Alzheimers Dis. 2013;36(2):401-8. doi: 10.3233/JAD-122329.
7
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系：一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
8
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者纵向血浆神经丝轻链与神经退行性变的关系。
JAMA Neurol. 2019 Jul 1;76(7):791-799. doi: 10.1001/jamaneurol.2019.0765.
9
CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.脑脊液生物标志物与淀粉样 PET 检测在 MCI 队列中的一致性和诊断准确性。
Acta Neurol Belg. 2019 Sep;119(3):445-452. doi: 10.1007/s13760-019-01112-8. Epub 2019 Mar 7.
10
Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.区域皮质变薄和脑脊液生物标志物可预测阿尔茨海默病谱系中日常功能的恶化。
J Alzheimers Dis. 2014;41(3):719-28. doi: 10.3233/JAD-132768.
引用本文的文献
1
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.阿尔茨海默病临床谱系中脑脊液淀粉样蛋白和 Tau 生物标志物的变化
JAMA Netw Open. 2025 Jul 1;8(7):e2519919. doi: 10.1001/jamanetworkopen.2025.19919.
2
Age-related hearing loss is not linked to cerebrospinal fluid levels of β-amyloid or p-tau181.年龄相关性听力损失与脑脊液中β-淀粉样蛋白或磷酸化tau蛋白181的水平无关。
Neurol Sci. 2024 Apr;45(4):1471-1480. doi: 10.1007/s10072-023-07143-7. Epub 2023 Oct 21.
3
Three potential neurovascular pathways driving the benefits of mindfulness meditation for older adults.三种潜在的神经血管途径驱动正念冥想对老年人的益处。
Front Aging Neurosci. 2023 Jun 29;15:1207012. doi: 10.3389/fnagi.2023.1207012. eCollection 2023.
4
Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease.阿尔茨海默病脑脊液蛋白质生物标志物的定量质谱分析。
Sci Data. 2023 May 9;10(1):261. doi: 10.1038/s41597-023-02158-3.
5
Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.阿尔茨海默病的性别差异：血浆 MMP-9 和疾病严重程度标志物。
Alzheimers Res Ther. 2022 Nov 2;14(1):160. doi: 10.1186/s13195-022-01106-4.
6
Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer's disease continuum.代谢和结构网络对阿尔茨海默病连续体中记忆的阶段依赖性差异影响。
Elife. 2022 Sep 2;11:e77745. doi: 10.7554/eLife.77745.
7
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.脑脊液 tau 水平与阿尔茨海默病中异常的神经元可塑性标志物有关。
Mol Neurodegener. 2022 Mar 28;17(1):27. doi: 10.1186/s13024-022-00521-3.
8
Presumed small vessel disease, imaging and cognition markers in the Alzheimer's Disease Neuroimaging Initiative.阿尔茨海默病神经影像学倡议中的疑似小血管疾病、影像学和认知标志物
Brain Commun. 2021 Oct 7;3(4):fcab226. doi: 10.1093/braincomms/fcab226. eCollection 2021.
9
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals.淀粉样蛋白前体（AT(N)）生物标志物与临床前阿尔茨海默病及认知正常个体神经精神症状的相关性。
Transl Neurodegener. 2021 Mar 31;10(1):11. doi: 10.1186/s40035-021-00236-3.
10
Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions.胶质和神经元退行性标志物与阿尔茨海默病脑脊液特征和认知功能的关联。
Alzheimers Res Ther. 2020 Aug 4;12(1):92. doi: 10.1186/s13195-020-00657-8.
本文引用的文献
1
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.临床前阿尔茨海默病及其结局：一项纵向队列研究。
Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4.
2
Neuropathologic basis of age-associated brain atrophy.与年龄相关的脑萎缩的神经病理学基础。
JAMA Neurol. 2013 May;70(5):616-22. doi: 10.1001/jamaneurol.2013.1957.
3
Meta-analysis of amyloid-cognition relations in cognitively normal older adults.认知正常老年人中淀粉样蛋白与认知的关系的荟萃分析。
Neurology. 2013 Apr 2;80(14):1341-8. doi: 10.1212/WNL.0b013e31828ab35d.
4
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.淀粉样β沉积、神经退行性变与散发性阿尔茨海默病认知衰退：一项前瞻性队列研究。
Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.
5
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.阿尔茨海默病病理生理过程的追踪：动态生物标志物的更新假设模型。
Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.
6
Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease.国际工作组标准与美国国立老化研究所-阿尔茨海默病协会标准比较。
Alzheimers Dement. 2012 Nov;8(6):560-3. doi: 10.1016/j.jalz.2011.10.008.
7
Injury markers predict time to dementia in subjects with MCI and amyloid pathology.在有 MCI 和淀粉样蛋白病理的受试者中，损伤标志物可预测痴呆发生时间。
Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.
8
Rates of decline in Alzheimer disease decrease with age.阿尔茨海默病的衰退率随年龄增长而降低。
PLoS One. 2012;7(8):e42325. doi: 10.1371/journal.pone.0042325. Epub 2012 Aug 2.
9
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).发展和评估阿尔茨海默病神经影像学倡议 (ADNI) 中记忆的综合评分。
Brain Imaging Behav. 2012 Dec;6(4):502-16. doi: 10.1007/s11682-012-9186-z.
10
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.用于执行功能的综合评分，在阿尔茨海默病神经影像学倡议（ADNI）的轻度认知障碍基线参与者中得到验证。
Brain Imaging Behav. 2012 Dec;6(4):517-27. doi: 10.1007/s11682-012-9176-1.
Zotero 插件